HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Related articles in JNM Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kraeber-Bodéré, F. Articles by Barbet, J. Search for Related Content PubMed PubMed Citation Articles by Kraeber-Bodéré, F. Articles by Barbet, J.

Targeting, Toxicity, and Efficacy of 2-Step, Pretargeted Radioimmunotherapy Using a Chimeric Bispecific Antibody and ¹³¹I-Labeled Bivalent Hapten in a Phase I Optimization Clinical Trial

¹ Nuclear Medicine Department, René Gauducheau Cancer Center, Nantes, France; ² Oncology Research Department, INSERM U601, Nantes, France; ³ Nuclear Medicine Department, Michalon Hospital, Grenoble, France; ⁴ Nuclear Medicine Department, Eugène Marquis Cancer Center, Rennes, France; ⁵ IBC Pharmaceuticals, Inc., Morris Plains, New Jersey; and ⁶ Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, New Jersey

Correspondence: For correspondence or reprints contact: Françoise Kraeber-Bodéré, MD, PhD, Oncology Research Department, INSERM U601, Institut de Biologie, 9 quai Moncousu, 44093 Nantes Cedex 1, France. E-mail: francoise.bodere{at}chu-nantes.fr

Safety, targeting, and antitumor efficacy of pretargeted radioimmunotherapy using anti-carcinoembryonic antigen (CEA) hMN-14 x m734 bispecific antibody (BsmAb) and ¹³¹I-di-diethylenetriamine pentaacetic acid (DTPA)-indium hapten were evaluated in a phase I study performed on patients with CEA-expressing tumors. Methods: Twenty-two patients with nonmedullary thyroid carcinoma (non-MTC) (group I, 13 patients) or medullary thyroid carcinoma (MTC) (group II, 9 patients) were enrolled. These patients received a 75 mg/m² (11 patients) or 40 mg/m² (11 patients) dose of BsmAb and escalating activities of ¹³¹I-di-DTPA-indium 5 d later. Toxicity and tumor response were assessed in 20 patients who received a therapeutic (>2.2 GBq) hapten dose of radioactivity. Results: The percentage of lesions detected by immunoscintigraphy after injection of the therapeutic dose of hapten was 70% on an anatomic-site basis. High bone uptake was relatively frequent. A transient grade I or II hepatic toxicity was observed in 5 patients (45%) injected with 75 mg/m² of BsmAb and in 1 patient (11%) injected with 40 mg/m². No other nonhematologic toxicity was observed. With 75 mg/m² of BsmAb, hematologic toxicity was high: 5 cases of grade III or IV leukopenia (45%) and 5 cases of grade III or IV thrombopenia (45%). With a 40 mg/m² dose of BsmAb, hematologic toxicity was reduced significantly: 3 cases of grade III or IV leukopenia (33%) and 1 case of grade III or IV thrombopenia (11%) (P = 0.02). Toxicity was significantly higher in MTC patients than in non-MTC patients (P = 0.019). Nine cases of tumor stabilization of 3 mo to more than 12 mo were observed (45%), 6 in the MTC group and 3 in the non-MTC group. The rate of disease stabilization was significantly higher with 75 mg/m² of BsmAb (64%) than with 40 mg/m² (22%) (P = 0.04). Human antimouse antibody elevation was observed in 1 patient (8%) and human antihuman antibody in 4 (33%). Conclusion: A BsmAb dose of 40 mg/m² and a 5-d interval appeared to be a better dose/schedule regimen, with acceptable toxicity. Under these conditions, the maximal tolerated activity was 3 GBq of ¹³¹I-di-DTPA-indium in MTC patients. In non-MTC patients, dose escalation should continue.

Key Words: bispecific antibodies • carcinoembryonic antigen • medullary thyroid carcinoma • pretargeting • radioimmunotherapy

Related articles in JNM:

Radioimmunotherapy of Solid Tumors: The Promise of Pretargeting Strategies Using Bispecific Antibodies and Radiolabeled Haptens

Raymond M. Reilly
JNM 2006 47: 196-199. [Full Text]  

This Month in JNM

JNM 2006 47: 7a-8a. [Full Text]  

This article has been cited by other articles:

				G. Liu, S. Dou, M. Rusckowski, and D. J. Hnatowich An experimental and theoretical evaluation of the influence of pretargeting antibody on the tumor accumulation of effector Mol. Cancer Ther., May 1, 2008; 7(5): 1025 - 1032. [Abstract] [Full Text] [PDF]

				D. M. Goldenberg, E. A. Rossi, R. M. Sharkey, W. J. McBride, and C.-H. Chang Multifunctional Antibodies by the Dock-and-Lock Method for Improved Cancer Imaging and Therapy by Pretargeting J. Nucl. Med., January 1, 2008; 49(1): 158 - 163. [Abstract] [Full Text] [PDF]

				A. Oudoux, P.-Y. Salaun, C. Bournaud, L. Campion, C. Ansquer, C. Rousseau, S. Bardet, F. Borson-Chazot, J.-P. Vuillez, A. Murat, et al. Sensitivity and Prognostic Value of Positron Emission Tomography with F-18-Fluorodeoxyglucose and Sensitivity of Immunoscintigraphy in Patients with Medullary Thyroid Carcinoma Treated with Anticarcinoembryonic Antigen-Targeted Radioimmunotherapy J. Clin. Endocrinol. Metab., December 1, 2007; 92(12): 4590 - 4597. [Abstract] [Full Text] [PDF]

				A. Sezeur, F.P. Chatelet, Ch. Cywiner, Cl. de Labriolle-Vaylet, C. Chastang, Cl. Billotey, M. Malafosse, D. Gallot, P. Betton, F. Montravers, et al. Pathology Underrates Colon Cancer Extranodal and Nodal Metastases; Ex vivo Radioimmunodetection Helps Staging Clin. Cancer Res., September 15, 2007; 13(18): 5592s - 5597s. [Abstract] [Full Text] [PDF]

				A. Machens, J. Ukkat, S. Hauptmann, and H. Dralle Abnormal Carcinoembryonic Antigen Levels and Medullary Thyroid Cancer Progression: A Multivariate Analysis Arch Surg, March 1, 2007; 142(3): 289 - 293. [Abstract] [Full Text] [PDF]

				A. Machens and H. Dralle Pretargeted Anti-Carcinoembryonic-Antigen Radioimmunotherapy for Medullary Thyroid Carcinoma J. Clin. Oncol., July 10, 2006; 24(20): e37 - e37. [Full Text] [PDF]

				R. M. Reilly Radioimmunotherapy of Solid Tumors: The Promise of Pretargeting Strategies Using Bispecific Antibodies and Radiolabeled Haptens J. Nucl. Med., February 1, 2006; 47(2): 196 - 199. [Full Text] [PDF]